Cronos Group (NASDAQ:CRON) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Cronos Group (NASDAQ:CRON) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other brokerages also recently issued reports on CRON. Sanford C. Bernstein reiterated a “market perform” rating and issued a $2.30 price target on shares of Cronos Group in a report on Wednesday, January 14th. Zacks Research lowered Cronos Group from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. TD Securities began coverage on Cronos Group in a research report on Tuesday. They issued a “buy” rating on the stock. Canaccord Genuity Group initiated coverage on Cronos Group in a research note on Tuesday, January 27th. They set a “buy” rating for the company. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Cronos Group in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $2.30.

Cronos Group Stock Performance

Shares of CRON opened at $2.67 on Friday. The business’s 50 day moving average is $2.65 and its 200 day moving average is $2.60. Cronos Group has a 12-month low of $1.60 and a 12-month high of $3.43. The company has a market capitalization of $1.02 billion, a PE ratio of -266.73 and a beta of 0.80.

Cronos Group (NASDAQ:CRON) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. The business had revenue of $58.39 million during the quarter, compared to analyst estimates of $38.51 million. Cronos Group had a negative net margin of 6.44% and a negative return on equity of 1.26%. Equities research analysts predict that Cronos Group will post -0.03 earnings per share for the current year.

Institutional Trading of Cronos Group

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Quinn Opportunity Partners LLC boosted its stake in Cronos Group by 73.0% during the second quarter. Quinn Opportunity Partners LLC now owns 7,437,944 shares of the company’s stock worth $14,206,000 after buying an additional 3,138,018 shares during the period. Tidal Investments LLC lifted its holdings in shares of Cronos Group by 5.3% in the 2nd quarter. Tidal Investments LLC now owns 5,653,070 shares of the company’s stock worth $10,797,000 after acquiring an additional 282,356 shares during the last quarter. MMCAP International Inc. SPC lifted its holdings in shares of Cronos Group by 56.1% in the 4th quarter. MMCAP International Inc. SPC now owns 2,761,059 shares of the company’s stock worth $7,262,000 after acquiring an additional 991,977 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Cronos Group by 1.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,506,210 shares of the company’s stock worth $6,591,000 after purchasing an additional 32,202 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Cronos Group by 4.0% during the 4th quarter. Renaissance Technologies LLC now owns 1,845,049 shares of the company’s stock valued at $4,852,000 after purchasing an additional 70,500 shares during the last quarter. Hedge funds and other institutional investors own 8.71% of the company’s stock.

More Cronos Group News

Here are the key news stories impacting Cronos Group this week:

• Positive Sentiment: Q4 revenue and EPS beat — Net revenue rose materially and results topped Street expectations: Q4 net revenue rose ~47% year-over-year to roughly $44.5M, and the company reported $0.02 EPS versus consensus ~$0.01, beating estimates. This topline and EPS surprise is the primary driver behind supportive price action. MarketBeat Earnings
• Positive Sentiment: Record revenue streak and brand strength — Cronos reported record Q4 and FY 2025 net revenue (eight consecutive quarters of record revenue in Israel) and noted PEACE NATURALS® leadership in that market, supporting top-line durability. GlobeNewswire Release
• Positive Sentiment: Strong balance sheet — Management highlighted an industry-leading cash and short-term investments position (~$832M), which reduces near-term financing risk and supports strategic optionality (M&A, Europe expansion, product investment). Yahoo Finance Release
• Neutral Sentiment: Strategic moves in Europe amid regulatory headwinds — Management discussed expansion/strategic initiatives in Europe, but flagged regulatory challenges that could slow commercialization; this is a potential growth driver but carries execution and regulatory risk. Yahoo Earnings Highlights
• Neutral Sentiment: Short-interest reporting ambiguous — Recent short-interest data in one feed showed no meaningful, actionable change (reporting anomalies); not a clear immediate catalyst. Monitor updated short-interest releases for clarity. Short Interest Note
• Negative Sentiment: Forex drove a Q4 GAAP loss — Currency translation/FX transactions swung the company to a Q4 loss (small per-share loss) and contributed to a FY net loss (~$9.4M), which investors may penalize as recurring FX volatility or accounting charges. Seeking Alpha FX Loss Story
• Negative Sentiment: Margins and profitability metrics mixed — While net margin on reported period activity looked strong, the company still posted a negative return on equity and a small full-year loss, keeping profitability questions on the table for some investors. MarketWatch Coverage

Cronos Group Company Profile

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.